Last $0.95 USD
Change Today +0.10 / 11.76%
Volume 600.0
BMRA On Other Exchanges
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

biomerica inc (BMRA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/16/14 - $1.10
52 Week Low
03/18/14 - $0.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOMERICA INC (BMRA)

Related News

No related news articles were found.

biomerica inc (BMRA) Related Businessweek News

No Related Businessweek News Found

biomerica inc (BMRA) Details

Biomerica, Inc. develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which may exist in the human body in extremely small concentrations. Its diagnostic products primarily include diabetes, gastrointestinal, food intolerances, and esoteric tests. The company provides its products primarily to distributors, hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

34 Employees
Last Reported Date: 08/29/14
Founded in 1971

biomerica inc (BMRA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $141.6K
Chief Financial Officer, Treasurer, Secretary...
Total Annual Compensation: $105.4K
President of Diagnostics Division
Total Annual Compensation: $141.6K
Compensation as of Fiscal Year 2014.

biomerica inc (BMRA) Key Developments

Biomerica, Inc. Announces Earnings Results for the First Fiscal Quarter Ended August 31, 2014

Biomerica Inc. announced earnings results for the first fiscal quarter ended August 31, 2014. For the quarter, net sales were $1,034,450 compared to $1,013,739 for the same period in the previous year. Net loss was $219,268 compared to $167,714 in fiscal 2014. The increase in the loss was primarily due to the increase in research and development spending, a majority of which was invested in the company's new Gastroenterology test and exploring the possibility of obtaining FDA clearance. Research and Development spending was $195,706 compared to $91,257 the previous quarter, an increase of $104,449. Net cash flow provided from operations was $143,641 compared to net cash used in operation of $376,271 in the same quarter the previous fiscal year, an increase of $519,912.

Biomerica Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended May 31, 2014

Biomerica Inc. reported earnings results for the fourth quarter and full year ended May 31, 2014. For the full year, the company reported net sales of $5,120,451 against net sales of $6,472,960 in fiscal 2013. Net loss was $215,660 for fiscal 2014 compared to net income of $536,957 for fiscal 2013. For the fourth quarter, net sales were $1,679,152 against net sales of $1,470,542 in the same fiscal quarter 2013. The pre-tax net loss for the fourth quarter fiscal 2014 was $51,423 compared to net income of $19,138 for fiscal 2013.

Biomerica to Supply Colorectal Screening Point of Care Test to Multinational Pharmaceutical Company

Biomerica Inc. announced it will supply its EZ Detect colorectal screening test to a multinational pharmaceutical company that has over $40 billion in revenues and over 70,000 employees worldwide. The EZ Detect product will be sold and marketed by the pharmaceutical company in one European country with the possibility of expanding into multiple other countries throughout Europe. The same pharmaceutical company currently distributes two other Biomerica point of care tests and the colorectal screening test is a new addition to the line. The terms of the agreement were not disclosed and will remain confidential. Biomerica's patented colorectal screening test (EZ Detect(TM)) is the simplest at home test available to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. EZ Detect is the only FDA cleared test that does not require handling of stool or have dietary restrictions. The EZ Detect pad is tossed into the toilet after a bowel movement. A change in the pad's color to blue/green, which would appear within two minutes, indicates the presence of blood in the stool. The pad is then simply flushed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRA:US $0.95 USD +0.10

BMRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $148.94 USD +0.82
Meridian Bioscience Inc $16.59 USD +0.10
Neogen Corp $44.65 USD +0.61
OraSure Technologies Inc $9.23 USD +0.03
Trinity Biotech PLC $16.83 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation BMRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at